METHACHOLINE CHLORIDE, USP 100 MG
METHACHOLINE CHLORIDE : 100 MG · DIN 02468263 · PANDA PHARMACEUTICALS INC.
Health Canada status: APPROVED
What is METHACHOLINE CHLORIDE, USP?
METHACHOLINE CHLORIDE, USP 100 MG contains METHACHOLINE CHLORIDE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02468263, held by PANDA PHARMACEUTICALS INC., supplied as POWDER FOR SOLUTION for INHALATION administration. Health Canada currently lists it as approved, status dated 15-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02468263 |
|---|---|
| Brand name | METHACHOLINE CHLORIDE, USP |
| Generic / active ingredient | METHACHOLINE CHLORIDE : 100 MG |
| Manufacturer | PANDA PHARMACEUTICALS INC. |
| Strength | 100 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INHALATION |
| Schedule | Prescription |
| ATC code | V04CX OTHER DIAGNOSTIC AGENTS |
| AHFS class | 36:89.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 15-Sep-2017 |
What can be used instead?
Other Canadian products sharing ATC code V04CX OTHER DIAGNOSTIC AGENTS. 9 of 50 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARIDOL | 20 MG | POWDER ; KIT | PHARMAXIS EUROPE LIMITED | MARKETED | DIN 02489562 |
| CYSVIEW | 100 MG | KIT ; POWDER FOR SOLUTION | PHOTOCURE ASA | MARKETED | DIN 02436639 |
| FLUORESCITE | 10 % | SOLUTION | ALCON CANADA INC | MARKETED | DIN 00505005 |
| METHACHOLINE OMEGA | 1600 MG | POWDER FOR SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02263912 |
| PATENT BLUE SODIUM INJECTION | 50 MG / 2 ML | SOLUTION | GUERBET | MARKETED | DIN 00405396 |
| PRE-PEN | 0.000060 M | SOLUTION | ALK-ABELLO INC | MARKETED | DIN 00328693 |
| PROVOCHOLINE | 100 MG | POWDER FOR SOLUTION | METHAPHARM INC | MARKETED | DIN 02239656 |
| PROVOCHOLINE | 1280 MG | POWDER FOR SOLUTION | METHAPHARM INC | MARKETED | DIN 02243834 |
| PROVOCHOLINE | 1600 MG | POWDER FOR SOLUTION | METHAPHARM INC | MARKETED | DIN 02288826 |
| DENTI-CARE DISCLOSING SOLUTION | 2 % | LIQUID | AMD MEDICOM INC | CANCELLED POST MARKET | DIN 02239704 |
Who else supplies OTHER DIAGNOSTIC AGENTS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OTHER DIAGNOSTIC AGENTS appears in 8 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.